<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33274002</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-0994</ISSN><JournalIssue CitedMedium="Internet"><Volume>2020</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Oxidative medicine and cellular longevity</Title><ISOAbbreviation>Oxid Med Cell Longev</ISOAbbreviation></Journal><ArticleTitle>Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention.</ArticleTitle><Pagination><StartPage>5021694</StartPage><MedlinePgn>5021694</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5021694</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2020/5021694</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2-5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Teresa Cunha-Oliveira et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cunha-Oliveira</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7382-0339</Identifier><AffiliationInfo><Affiliation>CNC-Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, Cantanhede, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montezinho</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6877-4286</Identifier><AffiliationInfo><Affiliation>CNC-Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, Cantanhede, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Investigation Vasco da Gama (CIVG), Escola Universit&#xe1;ria Vasco da Gama, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CNC-Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, Cantanhede, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Coimbra College of Agriculture, Polytechnic Institute of Coimbra (ESAC, IPC), Bencanta, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firuzi</LastName><ForeName>Omidreza</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2248-5198</Identifier><AffiliationInfo><Affiliation>Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saso</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4530-8706</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Paulo J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-5201-9948</Identifier><AffiliationInfo><Affiliation>CNC-Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, Cantanhede, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Filomena S G</ForeName><Initials>FSG</Initials><Identifier Source="ORCID">0000-0001-7143-8905</Identifier><AffiliationInfo><Affiliation>CNC-Center for Neuroscience and Cell Biology, University of Coimbra, UC Biotech Building, Biocant Park, Cantanhede, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oxid Med Cell Longev</MedlineTA><NlmUniqueID>101479826</NlmUniqueID><ISSNLinking>1942-0994</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="Y">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33274002</ArticleId><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="doi">10.1155/2020/5021694</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tafuri F., Ronchi D., Magri F., Comi G. P., Corti S. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Frontiers in Cellular Neuroscience. 2015;9:p. 336. doi: 10.3389/fncel.2015.00336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00336</ArticleId><ArticleId IdType="pmc">PMC4548205</ArticleId><ArticleId IdType="pubmed">26379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., et al. A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology International. 2015;6(1):p. 171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E. F., Shaw P. J., De Vos K. J. The role of mitochondria in amyotrophic lateral sclerosis. Neuroscience Letters. 2019;710, article 132933 doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Sakata T., Palumbo J., Akimoto M. A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS) (P3.189) Neurology. 2016;86</Citation></Reference><Reference><Citation>The Writing Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology. 2017;16(7):505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P. A., Henderson R. D. Effects of gender in amyotrophic lateral sclerosis. Gender Medicine. 2010;7(6):557&#x2013;570. doi: 10.1016/j.genm.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genm.2010.11.010</ArticleId><ArticleId IdType="pubmed">21195356</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis P. N., Rouleau G. A. Genetics of familial amyotrophic lateral sclerosis. Neurology. 2008;70(2):144&#x2013;152. doi: 10.1212/01.wnl.0000296811.19811.db.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000296811.19811.db</ArticleId><ArticleId IdType="pubmed">18180444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C., Roos P. M., Piehl F., Kamel F., Fang F. Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology. 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E., Ferrigno L., Leoncini E., Corbo M., Boccia S., Vanacore N. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: a systematic review. Neuroscience and Biobehavioral Reviews. 2016;66:61&#x2013;79. doi: 10.1016/j.neubiorev.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.04.007</ArticleId><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nature Reviews Neurology. 2013;9(11):617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B., Pamphlett R. Environmental insults: critical triggers for amyotrophic lateral sclerosis. Translational Neurodegeneration. 2017;6(1):p. 15. doi: 10.1186/s40035-017-0087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0087-3</ArticleId><ArticleId IdType="pmc">PMC5472994</ArticleId><ArticleId IdType="pubmed">28638596</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurologic Clinics. 2015;33(4):807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E., Majounie E., Waite A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H. X., Hentati A., Tainer J. A., et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261(5124):1047&#x2013;1051. doi: 10.1126/science.8351519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8351519</ArticleId><ArticleId IdType="pubmed">8351519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S. J., McKeown S. R., Rashid S. Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene. 2016;577(2):109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D. R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Synofzik M., Ronchi D., Keskin I., et al. Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Human Molecular Genetics. 2012;21(16):3568&#x2013;3574. doi: 10.1093/hmg/dds188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds188</ArticleId><ArticleId IdType="pubmed">22595972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I. P., Tripathi V. B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T. J., Bosco D. A., LeClerc A. L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Gendron T. F., Staff N. P. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clinic Proceedings. 2018;93(11):1617&#x2013;1628. doi: 10.1016/j.mayocp.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacman S. R., Bradley W. G., Moraes C. T. Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target? Molecular Neurobiology. 2006;33(2):113&#x2013;132. doi: 10.1385/MN:33:2:113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:33:2:113</ArticleId><ArticleId IdType="pubmed">16603792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Dong le W., Xie Y. Y., Wang X. P. Current therapy of drugs in amyotrophic lateral sclerosis. Current Neuropharmacology. 2016;14(4):314&#x2013;321. doi: 10.2174/1570159X14666160120152423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne E. C., Abbott B. M. Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. European Journal of Medicinal Chemistry. 2016;121:918&#x2013;925. doi: 10.1016/j.ejmech.2016.02.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.02.048</ArticleId><ArticleId IdType="pubmed">27012524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzino G., Irrera N., Cucinotta M., et al. Oxidative stress: harms and benefits for human health. Oxidative Medicine and Cellular Longevity. 2017;2017:13. doi: 10.1155/2017/8416763.8416763</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8416763</ArticleId><ArticleId IdType="pmc">PMC5551541</ArticleId><ArticleId IdType="pubmed">28819546</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand M. D. The sites and topology of mitochondrial superoxide production. Experimental Gerontology. 2010;45(7-8):466&#x2013;472. doi: 10.1016/j.exger.2010.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2010.01.003</ArticleId><ArticleId IdType="pmc">PMC2879443</ArticleId><ArticleId IdType="pubmed">20064600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kausar S., Wang F., Cui H. The role of mitochondria in reactive oxygen species generation and its implications for neurodegenerative diseases. Cells. 2018;7(12):p. 274. doi: 10.3390/cells7120274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7120274</ArticleId><ArticleId IdType="pmc">PMC6316843</ArticleId><ArticleId IdType="pubmed">30563029</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M. P. How mitochondria produce reactive oxygen species. The Biochemical Journal. 2009;417(1):1&#x2013;13. doi: 10.1042/BJ20081386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20081386</ArticleId><ArticleId IdType="pmc">PMC2605959</ArticleId><ArticleId IdType="pubmed">19061483</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkov A. A., Fiskum G., Chinopoulos C., et al. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. The Journal of Neuroscience. 2004;24(36):7779&#x2013;7788. doi: 10.1523/JNEUROSCI.1899-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1899-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729932</ArticleId><ArticleId IdType="pubmed">15356189</ArticleId></ArticleIdList></Reference><Reference><Citation>Tretter L., Adam-Vizi V. Generation of reactive oxygen species in the reaction catalyzed by&#x2009;-Ketoglutarate Dehydrogenase. The Journal of Neuroscience. 2004;24(36):7771&#x2013;7778. doi: 10.1523/JNEUROSCI.1842-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1842-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729921</ArticleId><ArticleId IdType="pubmed">15356188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunik V. I., Sievers C. Inactivation of the 2-oxo acid dehydrogenase complexes upon generation of intrinsic radical species. European Journal of Biochemistry. 2002;269(20):5004&#x2013;5015. doi: 10.1046/j.1432-1033.2002.03204.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1432-1033.2002.03204.x</ArticleId><ArticleId IdType="pubmed">12383259</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr A. L., Quinlan C. L., Perevoshchikova I. V., Brand M. D. A refined analysis of superoxide production by mitochondrial sn-glycerol 3-phosphate dehydrogenase. The Journal of Biological Chemistry. 2012;287(51):42921&#x2013;42935. doi: 10.1074/jbc.M112.397828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.397828</ArticleId><ArticleId IdType="pmc">PMC3522288</ArticleId><ArticleId IdType="pubmed">23124204</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller F. L., Liu Y., Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. The Journal of Biological Chemistry. 2004;279(47):49064&#x2013;49073. doi: 10.1074/jbc.M407715200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407715200</ArticleId><ArticleId IdType="pubmed">15317809</ArticleId></ArticleIdList></Reference><Reference><Citation>Omura T. Mitochondrial P450s. Chemico-Biological Interactions. 2006;163(1-2):86&#x2013;93. doi: 10.1016/j.cbi.2006.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2006.06.008</ArticleId><ArticleId IdType="pubmed">16884708</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman H. J., Kennedy J. Dihydroorotate-dependent superoxide production in rat brain and liver. A function of the primary dehydrogenase. Archives of Biochemistry and Biophysics. 1976;173(1):219&#x2013;224. doi: 10.1016/0003-9861(76)90252-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9861(76)90252-6</ArticleId><ArticleId IdType="pubmed">176947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hey-Mogensen M., Goncalves R. L. S., Orr A. L., Brand M. D. Production of superoxide/H2O2 by dihydroorotate dehydrogenase in rat skeletal muscle mitochondria. Free Radical Biology &amp; Medicine. 2014;72:149&#x2013;155. doi: 10.1016/j.freeradbiomed.2014.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.04.007</ArticleId><ArticleId IdType="pubmed">24746616</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan C. L., Orr A. L., Perevoshchikova I. V., Treberg J. R., Ackrell B. A., Brand M. D. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. The Journal of Biological Chemistry. 2012;287(32):27255&#x2013;27264. doi: 10.1074/jbc.M112.374629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.374629</ArticleId><ArticleId IdType="pmc">PMC3411067</ArticleId><ArticleId IdType="pubmed">22689576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaludercic N., Mialet-Perez J., Paolocci N., Parini A., di Lisa F. Monoamine oxidases as sources of oxidants in the heart. Journal of Molecular and Cellular Cardiology. 2014;73:34&#x2013;42. doi: 10.1016/j.yjmcc.2013.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2013.12.032</ArticleId><ArticleId IdType="pmc">PMC4048760</ArticleId><ArticleId IdType="pubmed">24412580</ArticleId></ArticleIdList></Reference><Reference><Citation>Rani V., Deep G., Singh R. K., Palle K., Yadav U. C. S. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sciences. 2016;148:183&#x2013;193. doi: 10.1016/j.lfs.2016.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2016.02.002</ArticleId><ArticleId IdType="pubmed">26851532</ArticleId></ArticleIdList></Reference><Reference><Citation>Birben E., Sahiner U. M., Sackesen C., Erzurum S., Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organization Journal. 2012;5(1):9&#x2013;19. doi: 10.1097/WOX.0b013e3182439613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WOX.0b013e3182439613</ArticleId><ArticleId IdType="pmc">PMC3488923</ArticleId><ArticleId IdType="pubmed">23268465</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S. C., Mead R. J., Shaw P. J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2006;1762(11-12):1051&#x2013;1067. doi: 10.1016/j.bbadis.2006.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.03.008</ArticleId><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodega G., Alique M., Puebla L., Carracedo J., Ram&#xed;rez R. M. Microvesicles: ROS scavengers and ROS producers. Journal of Extracellular Vesicles. 2019;8(1, article 1626654) doi: 10.1080/20013078.2019.1626654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2019.1626654</ArticleId><ArticleId IdType="pmc">PMC6586107</ArticleId><ArticleId IdType="pubmed">31258880</ArticleId></ArticleIdList></Reference><Reference><Citation>Phaniendra A., Jestadi D. B., Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian Journal of Clinical Biochemistry. 2015;30(1):11&#x2013;26. doi: 10.1007/s12291-014-0446-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-014-0446-0</ArticleId><ArticleId IdType="pmc">PMC4310837</ArticleId><ArticleId IdType="pubmed">25646037</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielska E., Smaga I., Gawlik M., et al. Oxidative Stress in Neurodegenerative Diseases. Molecular Neurobiology. 2016;53(6):4094&#x2013;4125. doi: 10.1007/s12035-015-9337-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9337-5</ArticleId><ArticleId IdType="pmc">PMC4937091</ArticleId><ArticleId IdType="pubmed">26198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam O. H., Rozhkov N. V., Shaw R., et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Reports. 2019;29(5):1164&#x2013;1177.e5. doi: 10.1016/j.celrep.2019.09.066. e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.09.066</ArticleId><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Calingasan N. Y., Chen J., Kiaei M., Beal M. F. Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiology of Disease. 2005;19(1-2):340&#x2013;347. doi: 10.1016/j.nbd.2005.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.01.012</ArticleId><ArticleId IdType="pubmed">15837590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante R. J., Browne S. E., Shinobu L. A., et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of Neurochemistry. 1997;69(5):2064&#x2013;2074. doi: 10.1046/j.1471-4159.1997.69052064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052064.x</ArticleId><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P. J., Ince P. G., Falkous G., Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Annals of Neurology. 1995;38(4):691&#x2013;695. doi: 10.1002/ana.410380424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380424</ArticleId><ArticleId IdType="pubmed">7574472</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson E. P., Henry Y. K., Henkel J. S., Smith R. G., Appel S. H. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology. 2004;62(10):1758&#x2013;1765. doi: 10.1212/WNL.62.10.1758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.62.10.1758</ArticleId><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R. G., Henry Y. K., Mattson M. P., Appel S. H. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Annals of Neurology. 1998;44(4):696&#x2013;699. doi: 10.1002/ana.410440419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440419</ArticleId><ArticleId IdType="pubmed">9778272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y., Nobukuni K., Takata H., Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurological Research. 2013;27(1):105&#x2013;108. doi: 10.1179/016164105x18430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164105x18430</ArticleId><ArticleId IdType="pubmed">15829169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Annals of Neurology. 1999;46(1):129&#x2013;131. doi: 10.1002/1531-8249(199907)46:1&lt;129::AID-ANA21&gt;3.0.CO;2-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199907)46:1&lt;129::AID-ANA21&gt;3.0.CO;2-Y</ArticleId><ArticleId IdType="pubmed">10401792</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J. H., Bartels C., P&#xf6;lking E., et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. Journal of Pineal Research. 2006;41(4):313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Santella R. M., Liu X., et al. Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis. 2009;9(3):177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Agar J., Durham H. Relevance of oxidative injury in the pathogenesis of motor neuron diseases. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2009;4(4):232&#x2013;242. doi: 10.1080/14660820310011278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310011278</ArticleId><ArticleId IdType="pubmed">14753657</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xec; M. T., Ferri A., Cozzolino M., Calabrese L., Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Research Bulletin. 2003;61(4):365&#x2013;374. doi: 10.1016/S0361-9230(03)00179-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(03)00179-5</ArticleId><ArticleId IdType="pubmed">12909279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft A., Resch J., Johnson D., Johnson J. Activation of the Nrf2-ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Experimental Neurology. 2007;207(1):107&#x2013;117. doi: 10.1016/j.expneurol.2007.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.05.026</ArticleId><ArticleId IdType="pmc">PMC2062571</ArticleId><ArticleId IdType="pubmed">17631292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling A. C., Schulz J. B., Brown R. H., Jr., Beal M. F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. Journal of Neurochemistry. 1993;61(6):2322&#x2013;2325. doi: 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb07478.x</ArticleId><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I., Dziewulska D., Kwiecinski H. Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis ALS. Folia Neuropathologica. 2004;42(3):151&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15535033</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Nagai R., Uchida K., et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Research. 2001;917(1):97&#x2013;104. doi: 10.1016/S0006-8993(01)02926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(01)02926-2</ArticleId><ArticleId IdType="pubmed">11602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen W. A., Fu W., Keller J. N., et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Annals of Neurology. 1998;44(5):819&#x2013;824. doi: 10.1002/ana.410440518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440518</ArticleId><ArticleId IdType="pubmed">9818940</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal M. F., Ferrante R. J., Browne S. E., Matthews R. T., Kowall N. W., Brown R. H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology. 1997;42(4):644&#x2013;654. doi: 10.1002/ana.410420416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420416</ArticleId><ArticleId IdType="pubmed">9382477</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Pan L.-H., Watanabe M., Konno H., Kato T., Itoyama Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurological Research. 2016;19(2):124&#x2013;128. doi: 10.1080/01616412.1997.11740784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.1997.11740784</ArticleId><ArticleId IdType="pubmed">9175139</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Pan L. H., Watanabe M., Kato T., Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neuroscience Letters. 1995;199(2):152&#x2013;154. doi: 10.1016/0304-3940(95)12039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(95)12039-7</ArticleId><ArticleId IdType="pubmed">8584246</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu G. N., Kumar A., Chandra R., et al. Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochemistry International. 2008;52(6):1284&#x2013;1289. doi: 10.1016/j.neuint.2008.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2008.01.009</ArticleId><ArticleId IdType="pubmed">18308427</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E., Factor-Litvak P., Santella R. M., Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology &amp; Medicine. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak J., D&#x119;bska-Vielhaber G., Vielhaber S., et al. Distinction of sporadic and familial forms of ALS based on mitochondrial characteristics. The FASEB Journal. 2018;33(3):4388&#x2013;4403. doi: 10.1096/fj.201801843r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201801843r</ArticleId><ArticleId IdType="pubmed">30550341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Cozzolino M., Crosio C., et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(37):13860&#x2013;13865. doi: 10.1073/pnas.0605814103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605814103</ArticleId><ArticleId IdType="pmc">PMC1557633</ArticleId><ArticleId IdType="pubmed">16945901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L., Ke Y., Luo C., Gozal D., Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience. 2007;144(3):991&#x2013;1003. doi: 10.1016/j.neuroscience.2006.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.09.064</ArticleId><ArticleId IdType="pmc">PMC1944995</ArticleId><ArticleId IdType="pubmed">17150307</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesaresi M. G., Amori I., Giorgi C., et al. Mitochondrial redox signalling by p66Shc mediates ALS-like disease through Rac1 inactivation. Human Molecular Genetics. 2011;20(21):4196&#x2013;4208. doi: 10.1093/hmg/ddr347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr347</ArticleId><ArticleId IdType="pubmed">21828072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles S., Destroismaisons L., Peyrard S. L., et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Human Molecular Genetics. 2013;22(19):3947&#x2013;3959. doi: 10.1093/hmg/ddt249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt249</ArticleId><ArticleId IdType="pmc">PMC5052069</ArticleId><ArticleId IdType="pubmed">23736301</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M. R., Johnson D. A., Johnson J. A. Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model. Neurobiology of Disease. 2011;43(3):543&#x2013;551. doi: 10.1016/j.nbd.2011.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.04.025</ArticleId><ArticleId IdType="pmc">PMC3139005</ArticleId><ArticleId IdType="pubmed">21600285</ArticleId></ArticleIdList></Reference><Reference><Citation>Igoudjil A., Magrane J., Fischer L. R., et al. In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space. The Journal of Neuroscience. 2011;31(44):15826&#x2013;15837. doi: 10.1523/JNEUROSCI.1965-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1965-11.2011</ArticleId><ArticleId IdType="pmc">PMC3249412</ArticleId><ArticleId IdType="pubmed">22049426</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord J. M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein) The Journal of Biological Chemistry. 1969;244(22):6049&#x2013;6055.</Citation><ArticleIdList><ArticleId IdType="pubmed">5389100</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi A. R., Culotta V. C. SOD1 integrates signals from oxygen and glucose to repress respiration. Cell. 2013;152(1-2):224&#x2013;235. doi: 10.1016/j.cell.2012.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.046</ArticleId><ArticleId IdType="pmc">PMC3552299</ArticleId><ArticleId IdType="pubmed">23332757</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai J., Zhang Z. Structural properties and interaction partners of familial ALS-associated SOD1 mutants. Frontiers in Neurology. 2019;10:p. 527. doi: 10.3389/fneur.2019.00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00527</ArticleId><ArticleId IdType="pmc">PMC6536575</ArticleId><ArticleId IdType="pubmed">31164862</ArticleId></ArticleIdList></Reference><Reference><Citation>Luquin N., Yu B., Trent R. J., Morahan J. M., Pamphlett R. An analysis of the entire SOD1 gene in sporadic ALS. Neuromuscular Disorders. 2008;18(7):545&#x2013;552. doi: 10.1016/j.nmd.2008.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2008.04.013</ArticleId><ArticleId IdType="pubmed">18504130</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt D. R., Lee M. K., Slunt H. S., et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proceedings of the National Academy of Sciences of United States of America. 1994;91(17):8292&#x2013;8296. doi: 10.1073/pnas.91.17.8292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.17.8292</ArticleId><ArticleId IdType="pmc">PMC44592</ArticleId><ArticleId IdType="pubmed">8058797</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim M. B., Kang J. H., Yim H. S., Kwak H. S., Chock P. B., Stadtman E. R. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proceedings of the National Academy of Sciences of United States of America. 1996;93(12):5709&#x2013;5714. doi: 10.1073/pnas.93.12.5709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.12.5709</ArticleId><ArticleId IdType="pmc">PMC39125</ArticleId><ArticleId IdType="pubmed">8650157</ArticleId></ArticleIdList></Reference><Reference><Citation>Koki&#x107; A. N., Stevi&#x107; Z., Stojanovi&#x107; S., et al. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Report. 2013;10(5):265&#x2013;270. doi: 10.1179/135100005x70242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/135100005x70242</ArticleId><ArticleId IdType="pubmed">16354415</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume A. G., Elliott J. L., Hoffman E. K., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics. 1996;13(1):43&#x2013;47. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratovitski T., Corson L. B., Strain J., et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Human Molecular Genetics. 1999;8(8):1451&#x2013;1460. doi: 10.1093/hmg/8.8.1451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.8.1451</ArticleId><ArticleId IdType="pubmed">10400992</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies F. M., Ince P. G., Shaw P. J. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochemistry International. 2002;40(6):543&#x2013;551. doi: 10.1016/S0197-0186(01)00125-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00125-5</ArticleId><ArticleId IdType="pubmed">11850111</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins C. M. J., Jung C., Ding H., Xu Z. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. The Journal of Neuroscience. 2002;22(6):p. RC215. doi: 10.1523/JNEUROSCI.22-06-j0001.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-06-j0001.2002</ArticleId><ArticleId IdType="pmc">PMC6758252</ArticleId><ArticleId IdType="pubmed">11886899</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D. The roles of free radicals in amyotrophic lateral sclerosis. Journal of Molecular Neuroscience. 1996;7(3):159&#x2013;167. doi: 10.1007/BF02736837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02736837</ArticleId><ArticleId IdType="pubmed">8906612</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J. S., Doucette P. A., Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annual Review of Biochemistry. 2005;74(1):563&#x2013;593. doi: 10.1146/annurev.biochem.72.121801.161647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.72.121801.161647</ArticleId><ArticleId IdType="pubmed">15952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim M. B., Chock P. B., Stadtman E. R. Copper, zinc superoxide dismutase catalyzes hydroxyl radical production from hydrogen peroxide. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(13):5006&#x2013;5010. doi: 10.1073/pnas.87.13.5006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.13.5006</ArticleId><ArticleId IdType="pmc">PMC54250</ArticleId><ArticleId IdType="pubmed">2164216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim M. B., Chock P. B., Stadtman E. R. Enzyme function of copper, zinc superoxide dismutase as a free radical generator. The Journal of Biological Chemistry. 1993;268(6):4099&#x2013;4105.</Citation><ArticleIdList><ArticleId IdType="pubmed">8382691</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman J. S., Est&#xe9;vez A. G., Crow J. P., Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends in Neurosciences. 2001;24(11):S15&#x2013;S20. doi: 10.1016/S0166-2236(00)01981-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(00)01981-0</ArticleId><ArticleId IdType="pubmed">11881740</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez A. G. Induction of Nitric Oxide -- Dependent Apoptosis in Motor Neurons by Zinc-Deficient Superoxide Dismutase. Science. 1999;286(5449):2498&#x2013;2500. doi: 10.1126/science.286.5449.2498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5449.2498</ArticleId><ArticleId IdType="pubmed">10617463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Beck M. V., Griffith J. D., Deshmukh M., Dokholyan N. V. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2018;115(18):4661&#x2013;4665. doi: 10.1073/pnas.1800187115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800187115</ArticleId><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Shang H., Qiu X., et al. Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. Neurochemical Research. 2012;37(4):835&#x2013;845. doi: 10.1007/s11064-011-0679-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-011-0679-8</ArticleId><ArticleId IdType="pubmed">22219129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezzi S. A., Urushitani M., Julien J. P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. Journal of Neurochemistry. 2007;102(1):170&#x2013;178. doi: 10.1111/j.1471-4159.2007.04531.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04531.x</ArticleId><ArticleId IdType="pubmed">17394546</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Daura X., Zagrovic B. Effect of oxidative damage on the stability and dimerization of superoxide dismutase 1. Biophysical Journal. 2016;110(7):1499&#x2013;1509. doi: 10.1016/j.bpj.2016.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2016.02.037</ArticleId><ArticleId IdType="pmc">PMC4833831</ArticleId><ArticleId IdType="pubmed">27074676</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D. M., Kwong L. K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Beeson G., Beeson C. C., Johnson J. A., Vargas M. R. Mitochondria-targeted catalase reverts the neurotoxicity of hSOD1G93A astrocytes without extending the survival of ALS-linked mutant hSOD1 mice. PLoS One. 2014;9(7, article e103438) doi: 10.1371/journal.pone.0103438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0103438</ArticleId><ArticleId IdType="pmc">PMC4108402</ArticleId><ArticleId IdType="pubmed">25054289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S., Kato M., Abe Y., et al. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathologica. 2005;110(2):101&#x2013;112. doi: 10.1007/s00401-005-1019-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1019-3</ArticleId><ArticleId IdType="pubmed">15983830</ArticleId></ArticleIdList></Reference><Reference><Citation>Killoy K. M., Harlan B. A., Pehar M., Helke K. L., Johnson J. A., Vargas M. R. Decreased glutathione levels cause overt motor neuron degeneration in hSOD1WT over-expressing mice. Experimental Neurology. 2018;302:129&#x2013;135. doi: 10.1016/j.expneurol.2018.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.01.004</ArticleId><ArticleId IdType="pmc">PMC5849514</ArticleId><ArticleId IdType="pubmed">29307609</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka O. B. V., Bulleid N. J. Forming disulfides in the endoplasmic reticulum. Biochimica et Biophysica Acta. 2013;1833(11):2425&#x2013;2429. doi: 10.1016/j.bbamcr.2013.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.02.007</ArticleId><ArticleId IdType="pubmed">23434683</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa-Diez C., Miguel V., Mennerich D., et al. Antioxidant responses and cellular adjustments to oxidative stress. Redox Biology. 2015;6:183&#x2013;197. doi: 10.1016/j.redox.2015.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2015.07.008</ArticleId><ArticleId IdType="pmc">PMC4534574</ArticleId><ArticleId IdType="pubmed">26233704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Amori I., Pesaresi M. G., Ferri A., Nencini M., Carr&#xec; M. T. Cysteine 111 affects aggregation and cytotoxicity of mutant Cu,Zn-superoxide dismutase associated with familial amyotrophic lateral sclerosis. The Journal of Biological Chemistry. 2008;283(2):866&#x2013;874. doi: 10.1074/jbc.M705657200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705657200</ArticleId><ArticleId IdType="pmc">PMC2842925</ArticleId><ArticleId IdType="pubmed">18006498</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa J., Yamada S. I., Ishigaki S., et al. Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. The Journal of Biological Chemistry. 2007;282(38):28087&#x2013;28095. doi: 10.1074/jbc.M704465200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M704465200</ArticleId><ArticleId IdType="pubmed">17666395</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle C., Carri M. T. Cysteine Modifications in the Pathogenesis of ALS. Frontiers in Molecular Neuroscience. 2017;10:p. 5. doi: 10.3389/fnmol.2017.00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00005</ArticleId><ArticleId IdType="pmc">PMC5253364</ArticleId><ArticleId IdType="pubmed">28167899</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmulappa R. K., Mai K. H., Srisuma S., Kensler T. W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Research. 2002;62(18):5196&#x2013;5203.</Citation><ArticleIdList><ArticleId IdType="pubmed">12234984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. M., Calkins M. J., Chan K., Kan Y. W., Johnson J. A. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. The Journal of Biological Chemistry. 2003;278(14):12029&#x2013;12038. doi: 10.1074/jbc.M211558200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211558200</ArticleId><ArticleId IdType="pubmed">12556532</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Korner S., Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurology Research International. 2012;2012:7. doi: 10.1155/2012/878030.878030</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T., Nioi P., Pickett C. B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. The Journal of Biological Chemistry. 2009;284(20):13291&#x2013;13295. doi: 10.1074/jbc.R900010200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R900010200</ArticleId><ArticleId IdType="pmc">PMC2679427</ArticleId><ArticleId IdType="pubmed">19182219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T., Sherratt P. J., Pickett C. B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annual Review of Pharmacology and Toxicology. 2003;43(1):233&#x2013;260. doi: 10.1146/annurev.pharmtox.43.100901.140229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.43.100901.140229</ArticleId><ArticleId IdType="pubmed">12359864</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J., Halligan E., Baptista M. J., et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain. 2005;128(Part 7):1686&#x2013;1706. doi: 10.1093/brain/awh503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh503</ArticleId><ArticleId IdType="pubmed">15872021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlette A., Krampfl K., Grothe C., Neuhoff N. ., Dengler R., Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology. 2008;67(11):1055&#x2013;1062. doi: 10.1097/NEN.0b013e31818b4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4906</ArticleId><ArticleId IdType="pubmed">18957896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D. C., Re D. B., Nagai M., Ischiropoulos H., Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(32):12132&#x2013;12137. doi: 10.1073/pnas.0603670103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0603670103</ArticleId><ArticleId IdType="pmc">PMC1562547</ArticleId><ArticleId IdType="pubmed">16877542</ArticleId></ArticleIdList></Reference><Reference><Citation>Marden J. J., Harraz M. M., Williams A. J., et al. Redox modifier genes in amyotrophic lateral sclerosis in mice. The Journal of Clinical Investigation. 2007;117(10):2913&#x2013;2919. doi: 10.1172/JCI31265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI31265</ArticleId><ArticleId IdType="pmc">PMC1974865</ArticleId><ArticleId IdType="pubmed">17853944</ArticleId></ArticleIdList></Reference><Reference><Citation>Harraz M. M., Marden J. J., Zhou W., et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. Journal of Clinical Investigation. 2008;118(2):659&#x2013;670. doi: 10.1172/jci34060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci34060</ArticleId><ArticleId IdType="pmc">PMC2213375</ArticleId><ArticleId IdType="pubmed">18219391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y. P., Che F. Y., Su Q. P., et al. Effects of mutant TDP-43 on the Nrf2/ARE pathway and protein expression of MafK and JDP2 in NSC-34 cells. Genetics and Molecular Research. 2017;16(2) doi: 10.4238/gmr16029638.</Citation><ArticleIdList><ArticleId IdType="doi">10.4238/gmr16029638</ArticleId><ArticleId IdType="pubmed">28510254</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D., Grubman A., Acevedo K., et al. TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Human Molecular Genetics. 2017;26(9):1732&#x2013;1746. doi: 10.1093/hmg/ddx093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx093</ArticleId><ArticleId IdType="pubmed">28334913</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Li X., Shi J., Guo Y., Li Z., Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience. 2010;169(4):1621&#x2013;1629. doi: 10.1016/j.neuroscience.2010.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.06.018</ArticleId><ArticleId IdType="pubmed">20600671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R. C., Chami A. A., de Assis D. R., et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142(5):1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fran&#xe7;ois-Moutal L., Perez-Miller S., Scott D. D., Miranda V. G., Mollasalehi N., Khanna M. Structural insights into TDP-43 and effects of post-translational modifications. Frontiers in Molecular Neuroscience. 2019;12:p. 301. doi: 10.3389/fnmol.2019.00301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00301</ArticleId><ArticleId IdType="pmc">PMC6934062</ArticleId><ArticleId IdType="pubmed">31920533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T. J., Hwang A. W., Unger T., Trojanowski J. Q., Lee V. M. Y. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. The EMBO Journal. 2012;31(5):1241&#x2013;1252. doi: 10.1038/emboj.2011.471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.471</ArticleId><ArticleId IdType="pmc">PMC3297986</ArticleId><ArticleId IdType="pubmed">22193716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. K., Chiang M. H., Toh E. K. W., Chang C. F., Huang T. H. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Letters. 2013;587(6):575&#x2013;582. doi: 10.1016/j.febslet.2013.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.038</ArticleId><ArticleId IdType="pubmed">23384725</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Scotter E. L., Nishimura A. L., et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Human Molecular Genetics. 2013;22(13):2676&#x2013;2688. doi: 10.1093/hmg/ddt117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt117</ArticleId><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Q., Holler C. J., Taylor G., et al. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. The Journal of Neuroscience. 2014;34(23):7802&#x2013;7813. doi: 10.1523/JNEUROSCI.0172-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0172-14.2014</ArticleId><ArticleId IdType="pmc">PMC4044245</ArticleId><ArticleId IdType="pubmed">24899704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo W., Mitra J., et al. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in amyotrophic lateral sclerosis. Nature Communications. 2018;9(1):p. 3683. doi: 10.1038/s41467-018-06111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06111-6</ArticleId><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai J. D., Ichida J. K. C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis. Neuroscience Letters. 2019;713, article 134523 doi: 10.1016/j.neulet.2019.134523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.134523</ArticleId><ArticleId IdType="pubmed">31568865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Arzberger T., Gr&#xe4;sser F. A., et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathologica. 2013;126(6):881&#x2013;893. doi: 10.1007/s00401-013-1189-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1189-3</ArticleId><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S. M., Arzberger T., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T. F., et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92(2):383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A., Ben-Dor I., Ottolenghi M., et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. eBioMedicine. 2019;50:274&#x2013;289. doi: 10.1016/j.ebiom.2019.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Brown R. H., Jr. Genetics of amyotrophic lateral sclerosis. Cold Spring Harbor Perspectives in Medicine. 2018;8(5) doi: 10.1101/cshperspect.a024125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024125</ArticleId><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho G. W., Kang B. Y., Kim S. H. Human angiogenin presents neuroprotective and migration effects in neuroblastoma cells. Molecular and Cellular Biochemistry. 2010;340(1-2):133&#x2013;141. doi: 10.1007/s11010-010-0410-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-010-0410-0</ArticleId><ArticleId IdType="pubmed">20174961</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Santiago R., Hoenig S., Lichtner P., et al. Identification of novel angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. Journal of Neurology. 2009;256(8):1337&#x2013;1342. doi: 10.1007/s00415-009-5124-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5124-4</ArticleId><ArticleId IdType="pmc">PMC2921066</ArticleId><ArticleId IdType="pubmed">19363631</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T. T., Johnson D. A., Raines R. T., Johnson J. A. Angiogenin activates the astrocytic Nrf2/antioxidant-response element pathway and thereby protects murine neurons from oxidative stress. The Journal of Biological Chemistry. 2019;294(41):15095&#x2013;15103. doi: 10.1074/jbc.RA119.008491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.008491</ArticleId><ArticleId IdType="pmc">PMC6791309</ArticleId><ArticleId IdType="pubmed">31431502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills A. M., Cronin S., Slowik A., et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology. 2009;73(1):16&#x2013;24. doi: 10.1212/WNL.0b013e3181a18674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a18674</ArticleId><ArticleId IdType="pmc">PMC2707108</ArticleId><ArticleId IdType="pubmed">19321847</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis P. N., Kabashi E., Dyck A., et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology. 2008;71(7):514&#x2013;520. doi: 10.1212/01.wnl.0000324997.21272.0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000324997.21272.0c</ArticleId><ArticleId IdType="pubmed">18695162</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeed M., Siddique N., Hung W. Y., et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology. 2006;67(5):771&#x2013;776. doi: 10.1212/01.wnl.0000227187.52002.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000227187.52002.88</ArticleId><ArticleId IdType="pubmed">16822964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng C. J., Wadleigh D. J., Gangopadhyay A., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. The Journal of Biological Chemistry. 2001;276(48):44444&#x2013;44449. doi: 10.1074/jbc.M105660200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105660200</ArticleId><ArticleId IdType="pubmed">11579088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S., Santamato A., Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatric Disease and Treatment. 2009;5:577&#x2013;595. doi: 10.2147/ndt.s7788.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ndt.s7788</ArticleId><ArticleId IdType="pmc">PMC2785861</ArticleId><ArticleId IdType="pubmed">19966906</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R. S., Traynor B. J., Cudkowicz M. E. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opinion on Emerging Drugs. 2007;12(2):229&#x2013;252. doi: 10.1517/14728214.12.2.229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728214.12.2.229</ArticleId><ArticleId IdType="pubmed">17604499</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M. E., Cutting F. B., Zhai P., et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology. 1996;39(2):147&#x2013;157. doi: 10.1002/ana.410390203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390203</ArticleId><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Michal Freedman D., Kuncl R. W., Weinstein S. J., Malila N., Virtamo J., Albanes D. Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2012;14(4):246&#x2013;251. doi: 10.3109/21678421.2012.745570.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.745570</ArticleId><ArticleId IdType="pmc">PMC3673294</ArticleId><ArticleId IdType="pubmed">23286756</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bustos F., Jim&#xe9;nez-Jim&#xe9;nez F. J., Molina J. A., et al. Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis. Journal of Neural Transmission. 1998;105(6-7):703&#x2013;708. doi: 10.1007/s007020050089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020050089</ArticleId><ArticleId IdType="pubmed">9826112</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Ikeda K., Kinoshita M. Vitamin A and E levels are normal in amyotrophic lateral sclerosis. Journal of the Neurological Sciences. 1995;132(2):193&#x2013;194. doi: 10.1016/0022-510X(95)00145-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00145-R</ArticleId><ArticleId IdType="pubmed">8543947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., O'Reilly E. J., Weisskopf M. G., et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. American Journal of Epidemiology. 2011;173(6):595&#x2013;602. doi: 10.1093/aje/kwq416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq416</ArticleId><ArticleId IdType="pmc">PMC3105261</ArticleId><ArticleId IdType="pubmed">21335424</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J. H., Kalmijn S., Groeneveld G.-J., et al. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2006;78(4):367&#x2013;371. doi: 10.1136/jnnp.2005.083378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083378</ArticleId><ArticleId IdType="pmc">PMC2077791</ArticleId><ArticleId IdType="pubmed">16648143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A., Weisskopf M. G., O'Reilly E. J., et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology. 2005;57(1):104&#x2013;110. doi: 10.1002/ana.20316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20316</ArticleId><ArticleId IdType="pubmed">15529299</ArticleId></ArticleIdList></Reference><Reference><Citation>Desnuelle C., Dib M., Garrel C., Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2009;2(1):9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11465936</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbussera A., Tremolizzo L., Brighina L., et al. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study. Neurological Sciences. 2006;27(3):190&#x2013;193. doi: 10.1007/s10072-006-0668-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-006-0668-x</ArticleId><ArticleId IdType="pubmed">16897634</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf M., Ecker D., Horowski R., et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Journal of Neural Transmission (Vienna) 2005;112(5):649&#x2013;660. doi: 10.1007/s00702-004-0220-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-004-0220-1</ArticleId><ArticleId IdType="pubmed">15517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappert E. J., Tangney C. C., Goetz C. G., et al. Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology. 1996;47(4):1037&#x2013;1042. doi: 10.1212/WNL.47.4.1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.4.1037</ArticleId><ArticleId IdType="pubmed">8857741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus R. L., Pasieczny R., Lariosa-Willingham K., Turner M. S., Jiang A., Trauger J. W. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. Journal of Neurochemistry. 2005;94(3):819&#x2013;827. doi: 10.1111/j.1471-4159.2005.03219.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03219.x</ArticleId><ArticleId IdType="pubmed">16033424</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldinger R., Katzberg H. D., Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews. 2012;(4, article Cd004157) doi: 10.1002/14651858.cd004157.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.cd004157.pub2</ArticleId><ArticleId IdType="pubmed">22513921</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen O. A., Dedeoglu A., Klivenyi P., Beal M. F., Bush A. I. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000;11(11):2491&#x2013;2493. doi: 10.1097/00001756-200008030-00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200008030-00029</ArticleId><ArticleId IdType="pubmed">10943709</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgunder J. M., Varriale A., Lauterburg B. H. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. European Journal of Clinical Pharmacology. 1989;36(2):127&#x2013;131. doi: 10.1007/BF00609183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00609183</ArticleId><ArticleId IdType="pubmed">2721538</ArticleId></ArticleIdList></Reference><Reference><Citation>Beretta S., Sala G., Mattavelli L., et al. Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. Neurobiology of Disease. 2003;13(3):213&#x2013;221. doi: 10.1016/S0969-9961(03)00043-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00043-3</ArticleId><ArticleId IdType="pubmed">12901835</ArticleId></ArticleIdList></Reference><Reference><Citation>Louwerse E. S., Weverling G. J., Bossuyt P. M. M., Meyjes F. E. P., de Jong J. M. B. V. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Archives of Neurology. 1995;52(6):559&#x2013;564. doi: 10.1001/archneur.1995.00540300031009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1995.00540300031009</ArticleId><ArticleId IdType="pubmed">7763202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresolin N., Bet L., Binda A., et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology. 1988;38(6):892&#x2013;899. doi: 10.1212/WNL.38.6.892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.38.6.892</ArticleId><ArticleId IdType="pubmed">3368070</ArticleId></ArticleIdList></Reference><Reference><Citation>Do T. Q., Schultz J. R., Clarke C. F. Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(15):7534&#x2013;7539. doi: 10.1073/pnas.93.15.7534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.15.7534</ArticleId><ArticleId IdType="pmc">PMC38780</ArticleId><ArticleId IdType="pubmed">8755509</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews R. T., Yang L., Browne S., Baik M., Beal M. F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(15):8892&#x2013;8897. doi: 10.1073/pnas.95.15.8892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.15.8892</ArticleId><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchetti J., Marino M., Papa S., et al. A mouse model of familial ALS has increased CNS levels of endogenous ubiquinol9/10 and does not benefit from exogenous administration of ubiquinol10. PLoS One. 2013;8(7, article e69540) doi: 10.1371/journal.pone.0069540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0069540</ArticleId><ArticleId IdType="pmc">PMC3720666</ArticleId><ArticleId IdType="pubmed">23936040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohmiya M., Tanaka M., Suzuki Y., Tanino Y., Okamoto K., Yamamoto Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. Journal of the Neurological Sciences. 2005;228(1):49&#x2013;53. doi: 10.1016/j.jns.2004.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2004.09.030</ArticleId><ArticleId IdType="pubmed">15607210</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina J. A., de Bustos F., Jim&#xe9;nez-Jim&#xe9;nez F. J., et al. Serum levels of coenzyme Q10 in patients with amyotrophic lateral sclerosis. Journal of Neural Transmission (Vienna) 2000;107(8-9):1021&#x2013;1026. doi: 10.1007/s007020070050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020070050</ArticleId><ArticleId IdType="pubmed">11041280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante K. L., Shefner J., Zhang H., et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65(11):1834&#x2013;1836. doi: 10.1212/01.wnl.0000187070.35365.d7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000187070.35365.d7</ArticleId><ArticleId IdType="pubmed">16344537</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy G., Kaufmann P., Buchsbaum R., et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006;66(5):660&#x2013;663. doi: 10.1212/01.wnl.0000201182.60750.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000201182.60750.66</ArticleId><ArticleId IdType="pubmed">16534103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J. L. P., Levy G., et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Annals of Neurology. 2009;66(2):235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Neves Carvalho A., Firuzi O., Joao Gama M., van Horssen J., Saso L. Oxidative stress and antioxidants in neurological diseases: is there still hope? Current Drug Targets. 2017;18(6):705&#x2013;718. doi: 10.2174/1389450117666160401120514.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450117666160401120514</ArticleId><ArticleId IdType="pubmed">27033198</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas M. R., Johnson D. A., Sirkis D. W., Messing A., Johnson J. A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. The Journal of Neuroscience. 2008;28(50):13574&#x2013;13581. doi: 10.1523/JNEUROSCI.4099-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4099-08.2008</ArticleId><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Zhang Y., Wen D., et al. The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model. Laboratory Investigation. 2013;93(7):825&#x2013;833. doi: 10.1038/labinvest.2013.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2013.73</ArticleId><ArticleId IdType="pubmed">23711824</ArticleId></ArticleIdList></Reference><Reference><Citation>van Muiswinkel F., Kuiperij H. The Nrf2-ARE signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Current Drug Targets. CNS and Neurological Disorders. 2005;4(3):267&#x2013;281. doi: 10.2174/1568007054038238.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007054038238</ArticleId><ArticleId IdType="pubmed">15975029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka K., Kanno T., Yanagisawa Y., et al. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS One. 2014;9(1, article e87728) doi: 10.1371/journal.pone.0087728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087728</ArticleId><ArticleId IdType="pmc">PMC3909264</ArticleId><ArticleId IdType="pubmed">24498180</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Tian X., Guo Y., Duan W., Bu H., Li C. Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biological &amp; Pharmaceutical Bulletin. 2011;34(8):1194&#x2013;1197. doi: 10.1248/bpb.34.1194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.34.1194</ArticleId><ArticleId IdType="pubmed">21804205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia N. K., Srivastava A., Katyal N., et al. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. Biochimica et Biophysica Acta. 2015;1854(5):426&#x2013;436. doi: 10.1016/j.bbapap.2015.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2015.01.014</ArticleId><ArticleId IdType="pubmed">25666897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Duan W., Guo Y., et al. Mitochondrial dysfunction in human TDP-43 transfected NSC34 cell lines and the protective effect of dimethoxy curcumin. Brain Research Bulletin. 2012;89(5-6):185&#x2013;190. doi: 10.1016/j.brainresbull.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2012.09.005</ArticleId><ArticleId IdType="pubmed">22986236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi M., Agah E., Nafissi S., et al. Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial. Neurotherapeutics. 2018;15(2):430&#x2013;438. doi: 10.1007/s13311-018-0606-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-018-0606-7</ArticleId><ArticleId IdType="pmc">PMC5935637</ArticleId><ArticleId IdType="pubmed">29352425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chico L., Ienco E. C., Bisordi C., et al. Amyotrophic lateral sclerosis and oxidative stress: a double-blind therapeutic trial after curcumin supplementation. CNS &amp; Neurological Disorders Drug Targets. 2018;17(10):767&#x2013;779. doi: 10.2174/1871527317666180720162029.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666180720162029</ArticleId><ArticleId IdType="pubmed">30033879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakotoarisoa M., Angelova A. Amphiphilic nanocarrier systems for curcumin delivery in neurodegenerative disorders. Medicines. 2018;5(4):p. 126. doi: 10.3390/medicines5040126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5040126</ArticleId><ArticleId IdType="pmc">PMC6313553</ArticleId><ArticleId IdType="pubmed">30477087</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripodo G., Chlapanidas T., Perteghella S., et al. Mesenchymal stromal cells loading curcumin-INVITE-micelles: a drug delivery system for neurodegenerative diseases. Colloids and Surfaces, B: Biointerfaces. 2015;125:300&#x2013;308. doi: 10.1016/j.colsurfb.2014.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2014.11.034</ArticleId><ArticleId IdType="pubmed">25524221</ArticleId></ArticleIdList></Reference><Reference><Citation>Neymotin A., Calingasan N. Y., Wille E., et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology &amp; Medicine. 2011;51(1):88&#x2013;96. doi: 10.1016/j.freeradbiomed.2011.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.03.027</ArticleId><ArticleId IdType="pmc">PMC3109235</ArticleId><ArticleId IdType="pubmed">21457778</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead R. J., Higginbottom A., Allen S. P., et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radical Biology &amp; Medicine. 2013;61:438&#x2013;452. doi: 10.1016/j.freeradbiomed.2013.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.018</ArticleId><ArticleId IdType="pmc">PMC3684770</ArticleId><ArticleId IdType="pubmed">23608463</ArticleId></ArticleIdList></Reference><Reference><Citation>Na H. K., Surh Y. J. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food and Chemical Toxicology. 2008;46(4):1271&#x2013;1278. doi: 10.1016/j.fct.2007.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2007.10.006</ArticleId><ArticleId IdType="pubmed">18082923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pervin M., Unno K., Nakagawa A., et al. Blood brain barrier permeability of (-)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice. Biochemistry and Biophysics Reports. 2017;9:180&#x2013;186. doi: 10.1016/j.bbrep.2016.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2016.12.012</ArticleId><ArticleId IdType="pmc">PMC5614586</ArticleId><ArticleId IdType="pubmed">28956003</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S. H., Kwon H., Kim K. S., et al. Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Toxicology. 2004;202(3):213&#x2013;225. doi: 10.1016/j.tox.2004.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2004.05.008</ArticleId><ArticleId IdType="pubmed">15337584</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S. H., Lee S. M., Kim H. Y., et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neuroscience Letters. 2006;395(2):103&#x2013;107. doi: 10.1016/j.neulet.2005.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.10.056</ArticleId><ArticleId IdType="pubmed">16356650</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Chen S., Li X., Luo G., Li L., le W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochemical Research. 2006;31(10):1263&#x2013;1269. doi: 10.1007/s11064-006-9166-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9166-z</ArticleId><ArticleId IdType="pubmed">17021948</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattee G. L., Post G. R., Gerber R. E., Bennett, Jr J. P. Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2009;4(2):90&#x2013;95. doi: 10.1080/14660820310012736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310012736</ArticleId><ArticleId IdType="pubmed">14506939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M., Bozik M. E., Ingersoll E. W., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine. 2011;17(12):1652&#x2013;1656. doi: 10.1038/nm.2579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2579</ArticleId><ArticleId IdType="pubmed">22101764</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzeisen R., Schwalenstoecker B., Gillardon F., et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride] The Journal of Pharmacology and Experimental Therapeutics. 2005;316(1):189&#x2013;199. doi: 10.1124/jpet.105.092312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.105.092312</ArticleId><ArticleId IdType="pubmed">16188953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Toninelli G., Maccarinelli G., Uberti D., Buerger E., Memo M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacology. 2010;10(1):p. 2. doi: 10.1186/1471-2210-10-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2210-10-2</ArticleId><ArticleId IdType="pmc">PMC2829550</ArticleId><ArticleId IdType="pubmed">20137065</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramova N. A., Cassarino D. S., Khan S. M., Painter T. W., Bennett J. P. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. Journal of Neuroscience Research. 2002;67(4):494&#x2013;500. doi: 10.1002/jnr.10127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10127</ArticleId><ArticleId IdType="pubmed">11835316</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozik M. E., Mather J. L., Kramer W. G., Gribkoff V. K., Ingersoll E. W. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. Journal of Clinical Pharmacology. 2011;51(8):1177&#x2013;1185. doi: 10.1177/0091270010379412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270010379412</ArticleId><ArticleId IdType="pubmed">20959524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicki S. A., Berry J. D., Ingersoll E., et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2013;14(1):44&#x2013;51. doi: 10.3109/17482968.2012.723723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.723723</ArticleId><ArticleId IdType="pubmed">22985432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M. E., van den Berg L. H., Shefner J. M., et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurology. 2013;12(11):1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira F. G., LaDow E., Moreno A., et al. Dexpramipexole is ineffective in two models of ALS related neurodegeneration. PLoS One. 2014;9(12, article e91608) doi: 10.1371/journal.pone.0091608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091608</ArticleId><ArticleId IdType="pmc">PMC4272269</ArticleId><ArticleId IdType="pubmed">25526593</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D. X., Reiter R., Manchester L., et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Current Topics in Medicinal Chemistry. 2002;2(2):181&#x2013;197. doi: 10.2174/1568026023394443.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026023394443</ArticleId><ArticleId IdType="pubmed">11899100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganie S. A., Dar T. A., Bhat A. H., et al. Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Research. 2016;19(1):21&#x2013;40. doi: 10.1089/rej.2015.1704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2015.1704</ArticleId><ArticleId IdType="pubmed">26087000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandi-Perumal S. R., BaHammam A. S., Brown G. M., et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotoxicity Research. 2013;23(3):267&#x2013;300. doi: 10.1007/s12640-012-9337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-012-9337-4</ArticleId><ArticleId IdType="pubmed">22739839</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon J., Acuna-Castroviejo D., Escames G., Tan D. X., Reiter R. J. Melatonin mitigates mitochondrial malfunction. Journal of Pineal Research. 2005;38(1):1&#x2013;9. doi: 10.1111/j.1600-079X.2004.00181.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00181.x</ArticleId><ArticleId IdType="pubmed">15617531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cook A., Kim J., et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 2013;55:26&#x2013;35. doi: 10.1016/j.nbd.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.008</ArticleId><ArticleId IdType="pmc">PMC3652329</ArticleId><ArticleId IdType="pubmed">23537713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Panayiotou E., Feldman M. L., et al. Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neuroscience Letters. 2013;548:170&#x2013;175. doi: 10.1016/j.neulet.2013.05.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.05.058</ArticleId><ArticleId IdType="pubmed">23748038</ArticleId></ArticleIdList></Reference><Reference><Citation>Barua S., Kim J. Y., Yenari M. A., Lee J. E. The role of NOX inhibitors in neurodegenerative diseases. IBRO Reports. 2019;7:59&#x2013;69. doi: 10.1016/j.ibror.2019.07.1721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibror.2019.07.1721</ArticleId><ArticleId IdType="pmc">PMC6709343</ArticleId><ArticleId IdType="pubmed">31463415</ArticleId></ArticleIdList></Reference><Reference><Citation>Saso L., Firuzi O. Pharmacological applications of antioxidants: lights and shadows. Current Drug Targets. 2014;15(13):1177&#x2013;1199. doi: 10.2174/1389450115666141024113925.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450115666141024113925</ArticleId><ArticleId IdType="pubmed">25341421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A. Y., Wang Q., Simonyi A., Sun G. Y. Botanical phenolics and brain health. Neuromolecular Medicine. 2008;10(4):259&#x2013;274. doi: 10.1007/s12017-008-8052-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-008-8052-z</ArticleId><ArticleId IdType="pmc">PMC2682367</ArticleId><ArticleId IdType="pubmed">19191039</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto M. C., Muotri A. R., Mu Y., Smith A. M., Cezar G. G., Gage F. H. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3(6):649&#x2013;657. doi: 10.1016/j.stem.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2008.10.001</ArticleId><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Heum&#xfc;ller S., Wind S., Barbosa-Sicard E., et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension. 2008;51(2):211&#x2013;217. doi: 10.1161/HYPERTENSIONAHA.107.100214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.107.100214</ArticleId><ArticleId IdType="pubmed">18086956</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumbull K. A., McAllister D., Gandelman M. M., et al. Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice. Neurobiology of Disease. 2012;45(1):137&#x2013;144. doi: 10.1016/j.nbd.2011.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.07.015</ArticleId><ArticleId IdType="pmc">PMC3710723</ArticleId><ArticleId IdType="pubmed">21820513</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanska J., Sokolowska M., Sarniak A., et al. Apocynin decreases hydrogen peroxide and nitrate concentrations in exhaled breath in healthy subjects. Pulmonary Pharmacology &amp; Therapeutics. 2010;23(1):48&#x2013;54. doi: 10.1016/j.pupt.2009.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2009.09.003</ArticleId><ArticleId IdType="pubmed">19786113</ArticleId></ArticleIdList></Reference><Reference><Citation>Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radical Biology &amp; Medicine. 2011;51(7):1289&#x2013;1301. doi: 10.1016/j.freeradbiomed.2011.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.06.033</ArticleId><ArticleId IdType="pmc">PMC3163726</ArticleId><ArticleId IdType="pubmed">21777669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. R., Zhou W. X., Zhang Y. X. Improvements in SOD mimic AEOL-10150, a potent broad-spectrum antioxidant. Military Medical Research. 2018;5(1):p. 30. doi: 10.1186/s40779-018-0176-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-018-0176-3</ArticleId><ArticleId IdType="pmc">PMC6125955</ArticleId><ArticleId IdType="pubmed">30185231</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M., Day B. J. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends in Pharmacological Sciences. 1999;20(9):359&#x2013;364. doi: 10.1016/S0165-6147(99)01336-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-6147(99)01336-X</ArticleId><ArticleId IdType="pubmed">10462758</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Kiaei M., Kipiani K., et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 2006;22(1):40&#x2013;49. doi: 10.1016/j.nbd.2005.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.09.013</ArticleId><ArticleId IdType="pubmed">16289867</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow J. P., Calingasan N. Y., Chen J., Hill J. L., Beal M. F. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Annals of Neurology. 2005;58(2):258&#x2013;265. doi: 10.1002/ana.20552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20552</ArticleId><ArticleId IdType="pubmed">16049935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichinohe H., Kuroda S., Yasuda H., et al. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Research. 2004;1029(2):200&#x2013;206. doi: 10.1016/j.brainres.2004.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.09.055</ArticleId><ArticleId IdType="pubmed">15542075</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Itoyama Y., Sobue G., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2014;15(7-8):610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Firuzi O., Miri R., Tavakkoli M., Saso L. Antioxidant therapy: current status and future prospects. Current Medicinal Chemistry. 2011;18(25):3871&#x2013;3888. doi: 10.2174/092986711803414368.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986711803414368</ArticleId><ArticleId IdType="pubmed">21824100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno A., Umemura K., Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. General Pharmacology. 1998;30(4):575&#x2013;578. doi: 10.1016/S0306-3623(97)00311-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-3623(97)00311-X</ArticleId><ArticleId IdType="pubmed">9522178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T., Yuki S., Watanabe T., Mitsuka M., Saito K. I., Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Research. 1997;762(1-2):240&#x2013;242. doi: 10.1016/S0006-8993(97)00490-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00490-3</ArticleId><ArticleId IdType="pubmed">9262182</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayasu Y., Nakaki J., Kawasaki T., et al. Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain. Journal of Pharmacological Sciences. 2007;103(4):434&#x2013;437. doi: 10.1254/jphs.SC0070014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jphs.SC0070014</ArticleId><ArticleId IdType="pubmed">17409627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jami M. S., Salehi-Najafabadi Z., Ahmadinejad F., et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochemistry International. 2015;90:134&#x2013;141. doi: 10.1016/j.neuint.2015.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2015.07.024</ArticleId><ArticleId IdType="pmc">PMC4675627</ArticleId><ArticleId IdType="pubmed">26232623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Teng C. H., Wu F. F., et al. Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation. Experimental and Therapeutic Medicine. 2019;18(1):467&#x2013;474. doi: 10.3892/etm.2019.7632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2019.7632</ArticleId><ArticleId IdType="pmc">PMC6580098</ArticleId><ArticleId IdType="pubmed">31281440</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno M., Mizuno T., Kato H., et al. The radical scavenger edaravone prevents oxidative neurotoxicity induced by peroxynitrite and activated microglia. Neuropharmacology. 2005;48(2):283&#x2013;290. doi: 10.1016/j.neuropharm.2004.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2004.10.002</ArticleId><ArticleId IdType="pubmed">15695167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang X., Chen S., et al. Prevention of motor neuron degeneration by novel iron chelators in SOD1&lt;sup&gt;G93A&lt;/sup&gt; transgenic mice of amyotrophic lateral sclerosis. Neurodegenerative Diseases. 2011;8(5):310&#x2013;321. doi: 10.1159/000323469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323469</ArticleId><ArticleId IdType="pubmed">21346313</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto N., Maki T., Pham L. D. D., et al. Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice. Stroke. 2013;44(12):3516&#x2013;3521. doi: 10.1161/STROKEAHA.113.002813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.113.002813</ArticleId><ArticleId IdType="pmc">PMC3985753</ArticleId><ArticleId IdType="pubmed">24072001</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M., Warita H., Mizuno H., Suzuki N., Yuki S., Itoyama Y. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Research. 2011;1382:321&#x2013;325. doi: 10.1016/j.brainres.2011.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.01.058</ArticleId><ArticleId IdType="pubmed">21276427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Wate R., Zhang J., et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Experimental Neurology. 2008;213(2):448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotrophic Lateral Sclerosis. 2006;7(4):241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18(Supplement 1):55&#x2013;63. doi: 10.1080/21678421.2017.1364269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1364269</ArticleId><ArticleId IdType="pubmed">28872920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., van den Berg L. H. Edaravone: a new treatment for ALS on the horizon? Lancet Neurology. 2017;16(7):490&#x2013;491. doi: 10.1016/S1474-4422(17)30163-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30163-1</ArticleId><ArticleId IdType="pubmed">28522180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. The New England Journal of Medicine. 1994;330(9):585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R. G., Bouchard J. P., Duquette P., et al. Clinical trials of riluzole in patients with ALS. Neurology. 1996;47(Issue 4) Supplement 2:86S&#x2013;92S. doi: 10.1212/wnl.47.4_suppl_2.86s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.47.4_suppl_2.86s</ArticleId><ArticleId IdType="pubmed">8858057</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M., Llad&#xf3; J., Rothstein J. D. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs. 2005;11(10):1343&#x2013;1364. doi: 10.1517/13543784.11.10.1343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.11.10.1343</ArticleId><ArticleId IdType="pubmed">12387699</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M. K. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Medicinal Research Reviews. 2019;39(2):733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rego A. C., Oliveira C. R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochemical Research. 2003;28(10):1563&#x2013;1574. doi: 10.1023/A:1025682611389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1025682611389</ArticleId><ArticleId IdType="pubmed">14570402</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh K. M., Hwang J. Y., Shin H. C., Koh J. Y. A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiology of Disease. 2000;7(4):375&#x2013;383. doi: 10.1006/nbdi.2000.0297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0297</ArticleId><ArticleId IdType="pubmed">10964608</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh J. Y., Kim D. K., Hwang J. Y., Kim Y. H., Seo J. H. Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. Journal of Neurochemistry. 1999;72(2):716&#x2013;723. doi: 10.1046/j.1471-4159.1999.0720716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0720716.x</ArticleId><ArticleId IdType="pubmed">9930745</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Xu Z.-F., Liu W., Xu B., Yang H.-B., Wei Y.-G. Riluzole-triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury-induced oxidative stress in rat cerebral cortex. Oxidative Medicine and Cellular Longevity. 2012;2012:534712. doi: 10.1155/2012/534705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/534705</ArticleId><ArticleId IdType="pmc">PMC3432391</ArticleId><ArticleId IdType="pubmed">22966415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala G., Arosio A., Conti E., et al. Riluzole selective antioxidant effects in cell models expressing amyotrophic lateral sclerosis endophenotypes. Clinical Psychopharmacology and Neuroscience. 2019;17(3):438&#x2013;442. doi: 10.9758/cpn.2019.17.3.438.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2019.17.3.438</ArticleId><ArticleId IdType="pmc">PMC6705104</ArticleId><ArticleId IdType="pubmed">31352711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg M. C., Halang L., Woods I., Coughlan K. S., PREHN J. H. M. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19(5-6):438&#x2013;445. doi: 10.1080/21678421.2017.1407796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407796</ArticleId><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M., Yamamoto Y., Miyazaki Y., Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Report. 2016;21(3):104&#x2013;112. doi: 10.1179/1351000215Y.0000000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215Y.0000000026</ArticleId><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaku K., Okabe K., Nakagawa T. NAD metabolism: implications in aging and longevity. Ageing Research Reviews. 2018;47:1&#x2013;17. doi: 10.1016/j.arr.2018.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2018.05.006</ArticleId><ArticleId IdType="pubmed">29883761</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A., Kaarniranta K., Kauppinen A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. International Journal of Molecular Sciences. 2013;14(2):3834&#x2013;3859. doi: 10.3390/ijms14023834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms14023834</ArticleId><ArticleId IdType="pmc">PMC3588074</ArticleId><ArticleId IdType="pubmed">23434668</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin S., St-Pierre J. PGC1&#x2009;and mitochondrial metabolism - emerging concepts and relevance in ageing and neurodegenerative disorders. Journal of Cell Science. 2012;125(21):4963&#x2013;4971. doi: 10.1242/jcs.113662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.113662</ArticleId><ArticleId IdType="pubmed">23277535</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Marcos P. J., Auwerx J. Regulation of PGC-1&#x3b1;, a nodal regulator of mitochondrial biogenesis. The American Journal of Clinical Nutrition. 2011;93(4):884S&#x2013;890S. doi: 10.3945/ajcn.110.001917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.110.001917</ArticleId><ArticleId IdType="pmc">PMC3057551</ArticleId><ArticleId IdType="pubmed">21289221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti G. M., Bilski A. E., Zhao W. Sirtuins as therapeutic targets of ALS. Cell Research. 2013;23(9):1073&#x2013;1074. doi: 10.1038/cr.2013.94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.94</ArticleId><ArticleId IdType="pmc">PMC3760621</ArticleId><ArticleId IdType="pubmed">23856645</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S., B&#xf6;selt S., Thau N., Rath K. J., Dengler R., Petri S. Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegenerative Diseases. 2013;11(3):141&#x2013;152. doi: 10.1159/000338048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000338048</ArticleId><ArticleId IdType="pubmed">22796962</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S., Choi J. R., Soon Shin K., Kang S. J. Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Research. 2012;1483:112&#x2013;117. doi: 10.1016/j.brainres.2012.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.09.022</ArticleId><ArticleId IdType="pubmed">23000195</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Song Y., Kincaid B., Bossy B., Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1&#x3b1;. Neurobiology of Disease. 2013;51:72&#x2013;81. doi: 10.1016/j.nbd.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.07.004</ArticleId><ArticleId IdType="pmc">PMC3992938</ArticleId><ArticleId IdType="pubmed">22819776</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N., Berg J., Clement J., et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes. Antioxidants &amp; Redox Signaling. 2019;30(2):251&#x2013;294. doi: 10.1089/ars.2017.7269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7269</ArticleId><ArticleId IdType="pmc">PMC6277084</ArticleId><ArticleId IdType="pubmed">29634344</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B. A., Pehar M., Sharma D. R., Beeson G., Beeson C. C., Vargas M. R. Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1) The Journal of Biological Chemistry. 2016;291(20):10836&#x2013;10846. doi: 10.1074/jbc.M115.698779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698779</ArticleId><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B. A., Killoy K. M., Pehar M., Liu L., Auwerx J., Vargas M. R. Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1-linked ALS mouse models. Experimental Neurology. 2020;327:p. 113219. doi: 10.1016/j.expneurol.2020.113219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113219</ArticleId><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="pubmed">32014438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Feng B., Kong D., et al. Production and validation of human induced pluripotent stem cell line from sporadic amyotrophic lateral sclerosis (SALS) Stem Cell Research. 2020;44:p. 101760. doi: 10.1016/j.scr.2020.101760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2020.101760</ArticleId><ArticleId IdType="pubmed">32203916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Zhu L., Qiu W., et al. Nicotinamide riboside enhances mitochondrial proteostasis and adult neurogenesis through activation of mitochondrial unfolded protein response signaling in the brain of ALS SOD1G93AMice. International Journal of Biological Sciences. 2020;16(2):284&#x2013;297. doi: 10.7150/ijbs.38487.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.38487</ArticleId><ArticleId IdType="pmc">PMC6949147</ArticleId><ArticleId IdType="pubmed">31929756</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan B. A., Pehar M., Killoy K. M., Vargas M. R. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. The FASEB Journal. 2019;33(6):7084&#x2013;7091. doi: 10.1096/fj.201802752R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802752R</ArticleId><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Rubia J. E., Drehmer E., Platero J. &#xc9;. L., et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019;20(1-2):115&#x2013;122. doi: 10.1080/21678421.2018.1536152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1536152</ArticleId><ArticleId IdType="pubmed">30668199</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M. P., Smith R. A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Review of Pharmacology and Toxicology. 2007;47(1):629&#x2013;656. doi: 10.1146/annurev.pharmtox.47.120505.105110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.47.120505.105110</ArticleId><ArticleId IdType="pubmed">17014364</ArticleId></ArticleIdList></Reference><Reference><Citation>Finichiu P. G., James A. M., Larsen L., Smith R. A. J., Murphy M. P. Mitochondrial accumulation of a lipophilic cation conjugated to an ionisable group depends on membrane potential, pH gradient and pK(a): implications for the design of mitochondrial probes and therapies. Journal of Bioenergetics and Biomembranes. 2013;45(1-2):165&#x2013;173. doi: 10.1007/s10863-012-9493-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-012-9493-5</ArticleId><ArticleId IdType="pubmed">23180142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelso G. F., Porteous C. M., Coulter C. V., et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. The Journal of Biological Chemistry. 2001;276(7):4588&#x2013;4596. doi: 10.1074/jbc.M009093200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M009093200</ArticleId><ArticleId IdType="pubmed">11092892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochem&#xe9; H. M., Kelso G. F., James A. M., et al. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion. 2007;7(Supplement):S94&#x2013;102. doi: 10.1016/j.mito.2007.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2007.02.007</ArticleId><ArticleId IdType="pubmed">17449335</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R. A., Murphy M. P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Annals of the New York Academy of Sciences. 2010;1201(1):96&#x2013;103. doi: 10.1111/j.1749-6632.2010.05627.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2010.05627.x</ArticleId><ArticleId IdType="pubmed">20649545</ArticleId></ArticleIdList></Reference><Reference><Citation>Solesio M. E., Prime T. A., Logan A., et al. The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. Biochimica et Biophysica Acta. 2013;1832(1):174&#x2013;182. doi: 10.1016/j.bbadis.2012.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2012.07.009</ArticleId><ArticleId IdType="pubmed">22846607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Chandran K., Kalivendi S. V., et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radical Biology &amp; Medicine. 2010;49(11):1674&#x2013;1684. doi: 10.1016/j.freeradbiomed.2010.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.08.028</ArticleId><ArticleId IdType="pmc">PMC4020411</ArticleId><ArticleId IdType="pubmed">20828611</ArticleId></ArticleIdList></Reference><Reference><Citation>McManus M. J., Murphy M. P., Franklin J. L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. The Journal of Neuroscience. 2011;31(44):15703&#x2013;15715. doi: 10.1523/JNEUROSCI.0552-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0552-11.2011</ArticleId><ArticleId IdType="pmc">PMC3334845</ArticleId><ArticleId IdType="pubmed">22049413</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M., Mao P., Calkins M. J., et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. Journal of Alzheimer's Disease. 2010;20(Supplement 2):S609&#x2013;S631. doi: 10.3233/JAD-2010-100564.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100564</ArticleId><ArticleId IdType="pmc">PMC3072711</ArticleId><ArticleId IdType="pubmed">20463406</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow B. J., Rolfe F. L., Lockhart M. M., et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Movement Disorders. 2010;25(11):1670&#x2013;1674. doi: 10.1002/mds.23148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23148</ArticleId><ArticleId IdType="pubmed">20568096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P., Cassina A., Pehar M., et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. The Journal of Neuroscience. 2008;28(16):4115&#x2013;4122. doi: 10.1523/JNEUROSCI.5308-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5308-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844766</ArticleId><ArticleId IdType="pubmed">18417691</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E., Cassina A., Mart&#xed;nez-Palma L., et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radical Biology &amp; Medicine. 2014;70:204&#x2013;213. doi: 10.1016/j.freeradbiomed.2014.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.02.019</ArticleId><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gane E. J., Weilert F., Orr D. W., et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver International. 2010;30(7):1019&#x2013;1026. doi: 10.1111/j.1478-3231.2010.02250.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2010.02250.x</ArticleId><ArticleId IdType="pubmed">20492507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielonka J., Joseph J., Sikora A., et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chemical Reviews. 2017;117(15):10043&#x2013;10120. doi: 10.1021/acs.chemrev.7b00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.7b00042</ArticleId><ArticleId IdType="pmc">PMC5611849</ArticleId><ArticleId IdType="pubmed">28654243</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M., Vargas M. R., Robinson K. M., et al. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. The Journal of Neuroscience. 2007;27(29):7777&#x2013;7785. doi: 10.1523/JNEUROSCI.0823-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0823-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672870</ArticleId><ArticleId IdType="pubmed">17634371</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Kiaei M., Damiano M., et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 2006;98(4):1141&#x2013;1148. doi: 10.1111/j.1471-4159.2006.04018.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04018.x</ArticleId><ArticleId IdType="pubmed">16895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K., Zhao G. M., Wu D., et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. The Journal of Biological Chemistry. 2004;279(33):34682&#x2013;34690. doi: 10.1074/jbc.M402999200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M402999200</ArticleId><ArticleId IdType="pubmed">15178689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K., Luo G., Giannelli S., Szeto H. H. Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochemical Pharmacology. 2005;70(12):1796&#x2013;1806. doi: 10.1016/j.bcp.2005.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2005.08.022</ArticleId><ArticleId IdType="pubmed">16216225</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S., Kranz J. E., Cole J., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis. 2009;9(1):4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A. C., Bendotti C., Blaugrund E., et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotrophic Lateral Sclerosis. 2010;11(1-2):38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiology of Disease. 2007;26(1):1&#x2013;13. doi: 10.1016/j.nbd.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.015</ArticleId><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E., Goldsteins G., Bart G. &#xc3;.&#xa8;., Koistinaho J., Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience. 2014;8:p. 131. doi: 10.3389/fncel.2014.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00131</ArticleId><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice J. R., Gregory-Evans C. Y., Shaw C. A. Animal models of amyotrophic lateral sclerosis: a comparison of model validity. Neural Regeneration Research. 2018;13(12):2050&#x2013;2054. doi: 10.4103/1673-5374.241445.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.241445</ArticleId><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: past, present and future. Brain Research. 2018;1693(Part A):1&#x2013;10. doi: 10.1016/j.brainres.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.03.024</ArticleId><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossolasco P., Sassone F., Gumina V., Peverelli S., Garzo M., Silani V. Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient. Stem Cell Research. 2018;30:61&#x2013;68. doi: 10.1016/j.scr.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.05.009</ArticleId><ArticleId IdType="pubmed">29800782</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo F. B., Cugola F. R., Fernandes I. R., Pignatari G. C., Beltr&#xe3;o-Braga P. C. Induced pluripotent stem cells for modeling neurological disorders. World Journal of Transplantation. 2015;5(4):209&#x2013;221. doi: 10.5500/wjt.v5.i4.209.</Citation><ArticleIdList><ArticleId IdType="doi">10.5500/wjt.v5.i4.209</ArticleId><ArticleId IdType="pmc">PMC4689931</ArticleId><ArticleId IdType="pubmed">26722648</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>